InflaRx N.V. (IFRX)
| Previous close | 1.3600 |
| Open | 1.3600 |
| Bid | 1.2900 x 100 |
| Ask | 1.4200 x 100 |
| Day's range | 1.3450 - 1.3600 |
| 52-week range | 1.1400 - 5.2000 |
| Volume | |
| Avg. volume | 227,746 |
| Market cap | 79.492M |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8300 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.03 |
GlobeNewswireInflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event to be held in New York City. InflaRx will participate in a panel titled, New Potential Dermatology Treatments for Psoriasis, Urticaria, and Alopecia scheduled on May 14, 2024, at 2:30 PM EDT /
ZacksInflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
InflaRx (IFRX) delivered earnings and revenue surprises of -50% and 99.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and potentially best-in-class oral C5aR inhibitor INF904 INF904 development will be initially targeted at chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), with initiation of a Phase IIa PK dose-ranging study expected by the end of 2024, with data availability anticipated in 2025 InflaRx is considering partnership options for
